Journal: Drugs-Real World Outcomes

Article type: Review Article

Title: Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan

Authors: Katsutoshi Hiramatsu¹, Annabel Barrett², Yasuhiko Miyata³, on behalf of PhRMA Japan Medical Affairs

Working Group 1

¹Amgen K.K., Tokyo, Japan

²Eli Lilly and Company Limited, Berkshire, UK

³Bristol Myers Squibb K.K., Tokyo, Japan

Address for correspondence: Katsutoshi Hiramatsu, Amgen K.K., Midtown Tower 9-7-1 Akasaka, Minato-ku, Tokyo

107-6239, Japan

Tel: +81-3-5293-9476; Fax: +81-6745-8022

E-mail address: khiramat@amgen.com

ORCID: 0000-0002-0746-7557

Short title: Real-World Data and Real-World Evidence in Japan

1

Supplementary Materials

Supplementary Table 1 Real-world databases available in Japan [1]

Database name	Summary of database	Database administrator	Registered patients (x10,000)	Data Period (year)
Hospital-based				
NHO Clinical Data	Database containing electronic medical record	NHO	190	2016~2019
Archives	information of 63 NHO hospitals	Headquarters		
MIA databank	Database containing DPC and receipt information of NHO 141 hospitals	NHO Headquarters	2,000	2010~2019
Convergence	A network that anonymizes and makes available	CCT	390	Unknown
CGRN	clinical data in medical institutions			~2019
RWD database	Integrated database of medical information such as	Real World	1,900	2003~2019
	electronic medical records, DPCs, and receipts	Data, Co., Ltd.		
Medical	A medical information database managed by PMDA	PMDA	470	2009~2019
Information	that consists of electronic medical records, receipts, and			
Database Network	DPC data.	M. F. ID	2044	2000 2010
EBM provider®	Database of inpatient and outpatient care at 385 acute- care institutions nationwide	Medical Data	2,844	2008~2019
JMDC Claims	Database of receipts and DPC data from multiple	Vision Co., Ltd. JMDC	880	2014~2019
Database (hospital-	medical institutions	JIVIDC	000	2014*2017
based)	incurcui insututions			
National Clinical	The Registry of Surgery, Interventions, Pathology, and	NCD	1,200	2011~2019
Database	Organ Cancer is operated mainly by the Japan Surgical			
	Society. Can be used in conjunction with DPC and			
	reception databases			
Insurance-based				
JMDC Claims	Database with multiple health insurance subscribers	JMDC	740	2005~2019
Database	(total number) as data sources			
(insurance-based) JammNet	Database of receipt data from multiple health insurance	IammNat	255	2008~2019
database	societies	Januare	233	2000~2019
MinaCare Database	Database of health insurance claims and health	MinaCare	630	2008~2018
	information from multiple health insurance societies			
Medi-Scope	Include almost all items of all receipt types (dental)	Kyowa Kikaku	666	2010~2019
		Ltd.		
Pharmacy-based				
Medi-Trend	External prescription database, number of collection	Kyowa Kikaku	647	2009~2019
	1 7 11	Ltd.		
IOVIA NDA doto	(approx. 16 million sheets/year)	ЮЛЛА	2 200	2015 2010
IQVIA NPA data	Compounding receipt database with data source of about 9,200 dispensing pharmacies (2018 total	IQVIA Solutions Japan	3,200	2015~2019
	prescriptions, 151 million)	K.K.		
JMIRI Pharmacy	Receipt database with external prescription as data	JMIRI	3,900	2006~2019
Claims DB	source		2,500	2000 2019
Nihon Chouzai	Database of prescriptions issued outside the hospital by	Japan Medical	1,623	2001~2019
Pharmacy Claims	medical institutions, various surveys on patients, DTC;	Research		
database	dispensing at 603 stores	Institute (Nihon-		
DED		Chouzai)	020	2015 2010
PFR	Out-of-hospital prescription analysis service;	PFR	820	2017~2019
	information contained in external prescriptions can be used, information can be provided without time lag			
Others	usca, information can be provided without time lag			
NHWS	Survey results from >2 million people in 10 major	SSRI	200	Before
	countries; prevalence, diagnosis and treatment rates of		_50	2000~2019
	>165 diseases, QOL, WPAI, severity and drugs used			

can be identified

PatientsMap Survey results database from >20,000 Japanese SSRI 16 2011~2018

2019 JP doctors; an estimate of consultation rates and patient

numbers of ~400 diseases, diseases requiring new drugs, and sales visits from >50 companies

CGRN Clinical Trial Global Research Network, CCT Convergence CT Inc., DPC Diagnosis Procedure Combination, DTC direct to consumer, JMDC Japan Medical Data Center Inc., JMIRI Japan Medical Information Research Institute, MIA Medical Information Analysis, NCD National Clinical Database, NHO National Hospital Organization, NHWS National Health and Wellness Survey, NPA National Prescription Audit, PMDA Pharmaceuticals and Medical Devices Agency, QOL quality of life, SSRI Social Survey Research Information Co., Ltd., PFR product flash report, WPAI work productivity and activity impairment

Supplementary Fig. 1. The search strategy

1. PubMed search strategy


((((Perspective[tiab] OR "guideline"[tiab] OR "regulation"[tiab] OR approach*[tiab] OR policy*[tiab]) AND ("HTA agency" OR "Regulatory agency" OR industry[tiab] OR "healthcare provider"[tiab] OR "healthcare payer"[tiab] OR stakeholder*[tiab]) AND ("real world data" OR "real world evidence" OR "real world outcome" OR "clinical effectiveness data" OR "hospital data" OR "electronic health records" OR "patient registry" OR "effectiveness"[tiab] OR "alternative study design") AND ("Pragmatic clinical trial" OR "observational design" OR "post-marketing study" OR comparative OR observ*[tiab] OR design*[tiab]) AND ("comparative effectiveness research" OR "outcomes research" OR "relative effectiveness assessment" OR "evidence"[tiab] OR "decision making"[tiab] OR "comparative effectiveness"[tiab]))) AND ("2010/01/01"[PDat] : "2019/12/31"[PDat]))

2. Ichushi-Web search strategy

("real world data (in Japanese)" OR "real world evidence (in Japanese)") AND ("definition (in Japanese)") AND (from January 1, 2010 to December 31, 2019[year of publication of the listing])

Supplementary Fig. 2. Collaborative research between SCRUM-Japan and pharmaceutical companies [2]. Reproduced with permission from Dr. Ohtsu Atsushi as well as Kagakuhyoronsya Co., Ltd. Copyright[©] 2018 with "New approaches in SCRUM-Japan Registry". All rights reserved

SCRUM-Japan: the Nationwide Cancer Genome Screening Project as Academic-Industrial Collaboration for Individualized Medicine in Japan



References

- Japanese Society for Pharmacoepidemiology. Databases available for pharmacoepidemiology researchers in Japan (information obtained from survey answers as of August 2020). 2020. http://www.jspe.jp/mt-static/FileUpload/files/JSPE_DB_TF_E.pdf [English version]. Accessed 9 April 2021.
- 2. Otsu A, Okamoto W, Fuse M, et al. From an academic perspective: new initiatives in the SCRUM-Japan Registry. Presented at: The 8th Joint Cancer New Drug Development Symposium. 2018.